Carvolix SA (0JZ.F)
Frankfurt · EUR · Healthcare · Medical Devices
€5.74 (-2.05%) as of
Key statistics
- Market cap
- 357.19M
- EPS (TTM)
- -0.64
- Dividend yield
- 0.00%
- 52-week range
- 1.28 – 7.20
- Beta
- 1.16
- Revenue (TTM)
- 1.59M
- Profit margin
- 0.00%
- Volume
- 498.00
About Carvolix SA
Carvolix SA, a medical technology company, develops and markets minimally invasive, minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company also offers TAVIPILOT Software, a robotic platform for transcatheter aortic valve implantation; TAVIPILOT Robot, mitral valve repair and replacement solutions; MITRAPILOT, a biomimetic transcatheter mitral valve; and Artedrone, an implantable artificial urinary sphincter. The company was formerly known as Affluent Medical SA and changed its name to Carvolix SA in February 2026. Carvolix SA was founded in 2011 and is headquartered in Aix-en-Provence, France.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Aix-en-Provence, France
- Employees
- 102
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.